ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efinopegdutide

Also written as “Efinopegdutide”, “JNJ-64565111” and “JNJ-64565111 Dose Level 1”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic, led by 2 companies.

Drug pageEfinopegdutide: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 23, 201815 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only80 open or runningphase 2since Mar 23, 2018Jun 24, 2016none ahead
Merck70 open or runningphase 2since Jun 28, 2021Jun 28, 2021none ahead
  • Named in Merck’s own pipeline as efinopegdutide (MK-6024), phase 2, as of Nov 2, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named efinopegdutideINNProposed as its International Nonproprietary Name in WHO's List 118 · before, JNJ-64565111
  2. Jun 28, 2021First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT04944992 · 145 enrolled · United States, Argentina, Australia and more
  3. May 17, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05877547 · 381 enrolled · United States, Austria, Belgium and more
  4. Sep 18, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT06052566 · 22 enrolled · United States
  5. Jun 13, 20242 phase 2 studies in Non-alcoholic Fatty Liver DiseaseNCT06465186, NCT06482112
  6. Nov 20, 2024Phase 1 study in HealthyNCT06701305 · 48 enrolled · United States
  7. Feb 18, 2025Phase 1 study in HealthyNCT06836037 · 56 enrolled · China

TargetBeta

“A synthetic peptide of oxyntomodulin conjugated to the constant region of human immunoglobulin G4 (IgG4) and dual glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist, with potential weight reducing and anti-diabetic activities and that may potentially be used for the treatment of non-alc…”NCIt, read by Claude
“Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
UBT251The United Laboratories Internationalphase 312
DR10624ruleHuadong Medicinephase 36
AZD9550AstraZenecaphase 27
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 7 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06836037Healthy · China1CompletedFeb 2, 202356
NCT06701305Healthy · United States1CompletedFeb 18, 202548
NCT06482112Non-alcoholic Fatty Liver Disease · United States, Puerto Rico2CompletedJun 27, 2025124
NCT06465186Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more2CompletedAug 3, 202685
NCT06052566Non-alcoholic Fatty Liver Disease · United States1CompletedDec 5, 202422
NCT05877547Non-alcoholic Fatty Liver Disease · United States, Austria, Belgium and more2CompletedDec 29, 2025381
NCT04944992Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more2CompletedOct 19, 2022145

How it is read

Names in the registry

  • “Efinopegdutide”, 6 entries
  • “JNJ-64565111”, 6 entries
  • “JNJ-64565111 Dose Level 1”, 2 entries
  • “JNJ-64565111 Dose Level 2”, 2 entries
  • “JNJ-64565111 Dose Level 3”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.